Stock Information

• Is It Time To Reevaluate Jazz Pharmaceuticals (JAZZ) After A 125% One Year Rally?
  Thu, May 7, 2026 2:21 PM
• ALX Oncology’s Evorpacept in Combination with Zanidatamab Generates Promising, Durable Response in Patients with Advanced HER2-Positive Breast Cancer and High CD47 Expression
  Thu, May 7, 2026 12:00 PM
• ALX Oncology Holdings Announces New Data Supporting Phase 1b/2 Clinical Trial For Evoracept In Combination With Jazz Pharmaceutical's Zanidatamab For Patients With Pre-Treated HER2-Positive Metastatic Breast Cancer
  Thu, May 7, 2026 8:06 AM
• Jazz Pharmaceuticals Delivered Strong Q1 on Broad-Based Portfolio Growth, RBC Says
  Wed, May 6, 2026 5:56 PM
• Jazz Pharmaceuticals Q1 Review: The Oncology Pivot Is Real, And The Market Is Still Mispricing It
  Wed, May 6, 2026 4:21 PM
• TD Cowen Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to $275
  Wed, May 6, 2026 3:28 PM
• JAZZ Stock Jumps as Q1 Earnings & Sales Surpass Expectations
  Wed, May 6, 2026 2:29 PM
• Jazz Pharmaceuticals plc Q1 2026 Earnings Call Summary
  Wed, May 6, 2026 12:30 PM
• RBC Capital Maintains Outperform on Jazz Pharmaceuticals, Raises Price Target to $258
  Wed, May 6, 2026 11:39 AM
• Barclays Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $234
  Wed, May 6, 2026 11:16 AM

Financial data not available